331 related articles for article (PubMed ID: 36077696)
1. Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges.
Zhao Y; Deng J; Rao S; Guo S; Shen J; Du F; Wu X; Chen Y; Li M; Chen M; Li X; Li W; Gu L; Sun Y; Zhang Z; Wen Q; Xiao Z; Li J
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077696
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Kazemi MH; Sadri M; Najafi A; Rahimi A; Baghernejadan Z; Khorramdelazad H; Falak R
Front Immunol; 2022; 13():1018962. PubMed ID: 36389779
[TBL] [Abstract][Full Text] [Related]
3. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors.
Wang S; Sun J; Chen K; Ma P; Lei Q; Xing S; Cao Z; Sun S; Yu Z; Liu Y; Li N
BMC Med; 2021 Jun; 19(1):140. PubMed ID: 34112147
[TBL] [Abstract][Full Text] [Related]
4. Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?
Li B
Front Immunol; 2022; 13():973881. PubMed ID: 36341370
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.
Granhøj JS; Witness Præst Jensen A; Presti M; Met Ö; Svane IM; Donia M
Expert Opin Biol Ther; 2022 May; 22(5):627-641. PubMed ID: 35414331
[TBL] [Abstract][Full Text] [Related]
6. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
Kumar A; Watkins R; Vilgelm AE
Front Immunol; 2021; 12():690499. PubMed ID: 34140957
[TBL] [Abstract][Full Text] [Related]
7. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.
Betof Warner A; Hamid O; Komanduri K; Amaria R; Butler MO; Haanen J; Nikiforow S; Puzanov I; Sarnaik A; Bishop MR; Schoenfeld AJ
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38423748
[TBL] [Abstract][Full Text] [Related]
8. The molecular mechanism of actions and clinical utilities of tumor infiltrating lymphocytes in gastrointestinal cancers: a comprehensive review and future prospects toward personalized medicine.
Piroozkhah M; Gholinezhad Y; Piroozkhah M; Shams E; Nazemalhosseini-Mojarad E
Front Immunol; 2023; 14():1298891. PubMed ID: 38077386
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocyte therapy: Clinical aspects and future developments in this breakthrough cancer treatment.
Lee H; Kim K; Chung J; Hossain M; Lee HJ
Bioessays; 2023 Jul; 45(7):e2200204. PubMed ID: 37166068
[TBL] [Abstract][Full Text] [Related]
10. Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers.
Tas L; Jedema I; Haanen JBAG
Curr Opin Oncol; 2023 Mar; 35(2):107-113. PubMed ID: 36607824
[TBL] [Abstract][Full Text] [Related]
11. Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances.
Wang X; Yuan Z; Li Z; He X; Zhang Y; Wang X; Su J; Wu X; Li M; Du F; Chen Y; Deng S; Zhao Y; Shen J; Yi T; Xiao Z
Front Immunol; 2024; 15():1354313. PubMed ID: 38426090
[TBL] [Abstract][Full Text] [Related]
12.
Jiménez-Reinoso A; Nehme-Álvarez D; Domínguez-Alonso C; Álvarez-Vallina L
Front Oncol; 2020; 10():593848. PubMed ID: 33680923
[TBL] [Abstract][Full Text] [Related]
13. Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Mullinax JE; Egger ME; McCarter M; Monk BJ; Toloza EM; Brousseau S; Jagasia M; Sarnaik A
Cancer J; 2022 Jul-Aug 01; 28(4):285-293. PubMed ID: 35880938
[TBL] [Abstract][Full Text] [Related]
14. Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy.
Diaz-Cano I; Paz-Ares L; Otano I
Int Rev Cell Mol Biol; 2022; 370():163-192. PubMed ID: 35798505
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.
Rohaan MW; van den Berg JH; Kvistborg P; Haanen JBAG
J Immunother Cancer; 2018 Oct; 6(1):102. PubMed ID: 30285902
[TBL] [Abstract][Full Text] [Related]
16. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
17. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Kverneland AH; Chamberlain CA; Borch TH; Nielsen M; Mørk SK; Kjeldsen JW; Lorentzen CL; Jørgensen LP; Riis LB; Yde CW; Met Ö; Donia M; Svane IM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607899
[TBL] [Abstract][Full Text] [Related]
18. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Landscape of Tumor-Infiltrating T and B Cells in Human Cancer.
Zheng M; Li YM; Liu ZY; Zhang X; Zhou Y; Jiang JL; Zhu P; Yang XM; Tang J; Chen ZN
Front Immunol; 2021; 12():731329. PubMed ID: 35069521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
